Inclusion Criteria:

- Age >18, either sex

- Histologically confirmed stage IV nasopharyngeal cancer

- One bone metastasis at least confirmed by imaging

- without chemotherapy or radiotherapy after bone metastasis

- Life expectancy > 6 M

- ECOG <= 2

- Adequate bone marrow reserve (WBC > 3.5 x 109/L, Neutrophile > 1.5 x 109/L,
Platelet 100 x 109/L, Hb > 90 g/L)

- Serum creatinine< 2.0 mg/dL (< 1.5 times the upper limit of the normal range for the
laboratory of the study center)

- Signed ICF

Exclusion Criteria:

- Women who are pregnant or in lactation

- Patients with hyperostosis

- Systemic treatment for another cancer within the year prior to study entry

- Previous or current treatment with any other bisphosphonates, bone- protecting,
cytotoxic or targeted therapy

- Initial serum creatinine >265 micromol/L and/or progressive renal disease

- Known hypersensitivity to any of the study drugs or to drugs with similar chemical
structures

- Use of investigational agents within 28 days of the Baseline visit, or participating
simultaneously in any other clinical studies

- Severe co-morbidity of any type that may interfere with assessment of the patient for
the study